Shares of GSK (GSK) moved lower after the FDA posted briefing documents ahead of its July 17 advisory panel meeting for Blenrep, an antibody-drug conjugate developed by GSK for the treatment of multiple myeloma. Shares of GSK are down 2% to $37.70 in late morning trading. The documents read: “Overall, the benefit-risk profile of Blenrep is strongly favorable…The safety profile is manageable, and ocular events were generally reversible when managed with dose reductions or dose delays enabling participants to continue treatment.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- ViiV Healthcare announces data from Phase IIIb VOLITION study
- ViiV Healthcare extends licensing agreement with Medicines Patent Pool
- GSK says FDA accepts application to review expanded use of RSV vaccine
- GSK’s Innovative Flu/COVID-19 Combo Vaccine Study Completes: Market Implications
- FDA willing to trade faster drug reviews for lower prices, Bloomberg reports